M1 Kliniken AG Reports Strong Financial Performance with 11% EBIT Growth and Strategic Focus on Medical Aesthetics

M1 Kliniken AG demonstrated robust financial performance during the first nine months of 2025, reporting an 11% increase in EBIT to EUR 24.5 million compared to EUR 22.1 million in the same period of 2024. The company achieved earnings per share of EUR 0.86, up from EUR 0.77 in the prior year period, reflecting continued profitable growth and effective implementation of efficiency measures.

Group revenue increased by 6.7% to EUR 274.3 million, up from EUR 257.2 million in the first nine months of 2024. EBITDA showed strong growth of 9%, reaching EUR 28.2 million compared to EUR 25.9 million in the previous year. The EBIT margin improved to 8.9% from 8.6%, indicating enhanced operational efficiency across the organization.

The Beauty segment emerged as the primary growth driver, with revenue increasing by 9.5% to EUR 77.8 million and EBIT surging by 29.7% to EUR 21.1 million. The segment's EBIT margin expanded significantly to 27.1% from 22.9% in the prior year period. This performance was supported by efficiency gains through optimized processes and higher utilization of medical capacities, combined with a targeted pricing strategy designed to attract new customer groups without compromising margin quality.

Meanwhile, the Trading segment recorded solid revenue growth of 6% to EUR 196.5 million, though EBIT declined by 41.4% to EUR 3.4 million. The company's strategic direction became clearer with the announcement that its 85% subsidiary, HAEMATO AG, has signed an agreement to sell HAEMATO Pharm GmbH to the PHOENIX group, one of Europe's leading healthcare providers based in Mannheim. This transaction, subject to usual antitrust approvals, aligns with M1 Kliniken AG's strategic focus on establishing itself as the world's leading vertically integrated pure-play provider of medical aesthetics.

The company's outlook remains positive, with plans to continue its profitable growth trajectory by expanding its network of national and international clinics. By 2029, the company expects to achieve revenue between EUR 200 million and EUR 300 million while maintaining a sustainable EBIT margin of at least 20%. This strategic vision includes establishing M1 Med Beauty as the world's leading brand for aesthetic medicine, building on its current position as the leading fully integrated provider of medical aesthetic services in Europe and Australia. The company currently operates 58 clinics across ten countries under the M1 Med Beauty brand, with all treatments performed exclusively by qualified physicians adhering to uniform, high medical standards at market-leading prices. Additional information about the company's operations and strategic direction can be found at https://www.m1-kliniken.de.